

**Brighton and Sussex University Hospitals NHS Trust**

**Study Delivery Q3 2019-2020**

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/YH/0228	222492	CALM- 2 – CONTROLLING AND LOWERING BLOOD PRESSURE WITH THE MOBIUSHD®	Number Agreed	2	2	Date Agreed	31/05/2019	0	19/02/2019	0	Withdrawn By Host
17/LO/1519	230794	A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Feasibility of the Leaflex™ Performer (The Leaflex™ Performer Feasibility Study)	Number Agreed	5	5	Date Agreed	01/05/2017	3	09/05/2019	3	Withdrawn By Host
18/LO/0727	245123	Post-Market Clinical Follow-Up Study to Monitor Device Performance and Outcomes of the CENTERA Heart Valve System	Number Agreed	5	5	Date Agreed	30/09/2019	13	25/07/2019	13	Recruitment Finished
10/H0808/138	52056	The European Bifurcation Coronary study; A randomised comparison of provisional Tstenting versus a systematic two stent strategy in large calibre true bifurcation	Range Agreed	20	30	Not Available / Not Agreed			25/01/2019	23	Recruitment Finished
17/LO/2058	231907	A PROSPECTIVE, MULTICENTER, NON-RANDOMIZED, POST-MARKET CLINICAL FOLLOW-UP STUDY TO CONFIRM SAFETY AND PERFORMANCE OF THE COHEREX WAVECREST® LEFT ATRIAL APPENDAGE OCCLUSION SYSTEM IN CURRENT MEDICAL PRACTICE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRI	Number Agreed	2	2	Date Agreed	28/02/2018	2	29/10/2019	2	Withdrawn By Host
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy. SMART CRT	Number Agreed	10	72	Date Agreed	20/10/2019	7	28/10/2019	7	Recruitment Finished
10/H1010/58	60742	A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy	Number Agreed	12	12	Not Available / Not Agreed			09/04/2019	2	Recruitment Finished